Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rapamycin-Resistant T Cell Therapy for Multiple Myeloma
NCT01239368Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Nov 2010
- Primary completion
- Aug 2017
- Modality
- Bone Marrow HSCs, Peripheral Blood HSCs
- Countries
- 1
01
Overview
A Phase 2 trial of rapa-201 in multiple myeloma (MM), sponsored by National Cancer Institute. Started Nov 2010; status: terminated.
02
Drugs
rapa-201
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01239368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01239368.